Technology Offerings

Method for the measurement of intraocular pressure

The present invention describes a measur-ing device that allows for the accurate de-termination of intraocular pressure by attaching a measuring body to the closed eyelid. The measuring principle is based on the subjective intraocular pressure es-timation by the palpating finger and will be implemented in an objective measuring method by the device described herein.
The existing development is based on an approximation of the contour of the in-dented eye which flattens the enveloping tissue and simultaneously adapts to the contour of the eye’s surface. In the broad-est sense it is as an adaptation of covering eyelid tissue to an expanded surface of the eye. The device basically consists of two pressure units made from silicone, which are independently and resiliently mounted from another. The pressure of the first membrane is applied via a struc-turally designed spring and serves to smooth the upper eyelid and the indirect fixation of the eyeball. The pressure of the second membrane is applied via two springs and is continuously increased to-wards measurement point when no further flattening of the second membrane is visi-ble. Consequently, the pressure character-istics of the eye are transferred from the first membrane to the second membrane. The flattening is monitored by an LED light reflex and the maximum value can thus be easily determined.
The present invention is of particular ad-vantage for measurements of intraocular pressure in patients with an injured or dis-eased cornea.

Connection between tubular composite columns and concrete slab

This steel mounting part provides a fully rigid connectiv ity between tubular composite column and reinforced concrete slab.
Simultaneously, it solves punching shear problems in the reinforced concrete slab by increasing its shear capacity.

For the inhibition of inflammatory immune responses: Novel degradation-stable inhibitors of the cPLA2

The invented substances have been characterized with regard to the inhibition of the cPLA2 (IC50 in the submicromolar range) and metabolic stability (tested in rat liver homogenates). The inventors are currently conducting such experiments with further, newly generated derivatives of the same inhibitor family. On behalf of the Westfalian Wilhelms-University of Muenster, PROvendis offers access to rights for commercial use as well as the opportunity for further co-development. The cPLA2 has been identified as target for the inhibition of inflammatory immune responses. The invented substances are of high interest for any pharma company with an immunological pipeline and may constitute the first-in-class cPLA2 inhibitors for systemic application.

Differential diagnosis of dementia with Lewy bodies and Parkinson’s disease

Parkinson's disease (PD) is a neurological movement disorder. Atypical Parkinson syndromes arise from other neurodegenerative diseases like Dementia with Lewy bodies (DLB). The accurate distinction between them is challenging. Our scientists developed a new diagnostic test to differentiate between DLB, PD and other neuropathies.

Thin film area scan device for hyperspectral imagers

For two-dimensional film thickness determination, a measurement system based on a hyperspectral imager has been developed for the first time. A head forms a measurement line. Reflection of the measurement object is displayed on the entrance slit of the hyperspectral imager. From the spectral reflectance data of each locally resolvable pixel of the examined object the layer height is reconstructed. If the measurement object is moving uniformly, combined measurement lines are resulting in a two-dimensional measuring surface. In addition, for each locally resolvable pixel the distance between head and measurement object can be determined.

Peripherally acting NMDAR Antagonists as new Antidiabetic Medication

According to the International Diabetes Federation (IDF), diabetes affects close to 400 million people worldwide and caused 500 billion Euros in health expenditure in 2013. In preclinical and clinical trials, the NMDA receptor antagonist dextrorphan (DXO) and its prodrug dextromethorphan have been shown to harbor antidiabetic properties (Marquard et al., Nat Med 2015). In addition, DXO was shown to protect mouse and human pancreatic beta cells from cell death during a diabetogenic setting.
DXO is well tolerated and sold as over-the-counter (OTC) medication for more than 50 years. However, adverse events are observed, which are likely caused by the action of DXO on the central nervous system (CNS). Here, the scientists developed DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.
The inventors now aim to demonstrate the expected novel clinical benefit in clinical studies.

Page
1 36 37 38 39 40 518